Team
We are a diverse group – molecular biologists, MDs, PharmDs, tumor immunologists, stem cell biologists and computational scientists – at all career stages. We architect strategies to dissect and manipulate immune cell identity.
Members
Alumni
Luis Galán Palma
Former Erasmus Student
Currently PhD Student at Anna Bigas Lab. Hospital del Mar Institute, Barcelona, Spain
Ariane Tenreiro
Former MSc Student
Currently Research Fellow at David Breault Lab. Harvard Stem Cell Institute, Boston, US
Svandís Sæmundsdóttir
Former Computational MSc Student
Currently Associate Consultant at Cerner Corporation
Sara Llorente Armijo
Former MSc student
Currently PhD Student at MRC Clinical Sciences Center, Imperial College, London, UK
Andreia Gomes
Former PhD Student
Currently Business Developer and Inside Sales at NZYTech
Monika Malz
Former Kapital Ludzki Student
Currently PhD Student at DZNE, Bonn, Germany
Rigveda Bhave
Former MSc Student
Currently PhD Student at Vrije University of Brussels, Belgium
Kritika Shaiv
Former MSc Student
Currently PhD Student at National Tsing Hua University, Hsinchu City, Taiwan
Raquel Marques
Former Student
Currently PhD Student at ICVS School of Medicine, Minho University, Braga, Portugal
Catarina Silva
Former MSc Student
Currently PhD Student at i3S, Porto, Portugal
Raquel Santos
Former MSc Student
Currently PhD Student at CNC, Coimbra, Portugal
Frederick Korbel
Former BSc Student
Currently MSc Student at Charité - Berlin University, Berlin, Germany
Cláudia Azenha
Former MSc Student
Currently Researcher at Biocant Park, Portugal
Jakob Haider
Former BSc Student
Currently MSc Student at Lund University, Lund, Sweden
Jennyfer Pastor Gómez
Former MSc Student
Currently Intern at SYNLAB Analytics & Services (A&S)
Tasnim Zahan
Former MSc Student
Currently Process Development Technician at Immunicum
Diego Cabrera
Former MSc Student
Currently Clinical Research Associate at Parexel
Cristiana Pires
Former Postdoctoral Fellow
Currently CEO at Asgard Therapeutics
Fábio Rosa
Former PhD Student
Currently Head of Research at Asgard Therapeutics
Marta Pinto
Former Postdoctoral Fellow
Hreinn Benónísson
Former Postdoctoral Fellow
Alexander Kuzmin
Former MSc Student
Nina Lipjankić
Former MSc Student
Eda Sağlam
Former MSc Student
João Catarino
Former MSc Student
Collaborators
Caetano Reis e Sousa
Francis Crick Institute
Dendritic Cells. London, UK
Jenny Hansson
Lund University
Proteomics. Lund, Sweden
Stefan Scheding
Lund University
Mesenchymal Stem Cells. Lund, Sweden
Stefan Karlsson
Lund University
Gene Therapy. Lund, Sweden
Katharina Lahl
Lund University
Dendritic Cells. Lund, Sweden
Raquel Almeida
i3S - University of Porto
Cancer Stem Cells. Porto, Portugal
Marella de Brujin
Weatherall Institute of Molecular Medicine
Developmental Hematopoiesis. Oxford, UK
Ewa Sitnicka
Lund University
NK Cell Biology. Lund, Sweden
Stephanie Hugues
University of Geneva
Tumor Immunology. Geneva, Switzerland
Michal Bassani Sternberg
UNIL - Lausanne University
Immunopeptidomics. Lausanne, Switzerland
Johan Bengzon
Skåne University Hospital
Clinical. Neurosurgery. Lund, Sweden
Dung-Fang Lee
MD Anderson Cancer Center
Kinases and Phosphatases. Texas, U.S.
Kenichi Miharada
Lund University
Cancer Cell Reprogramming. Lund, Sweden
Kees-Jan Pronk
Skåne University Hospital
Clinical. Hematology. Lund, Sweden
Göran B Jönsson
Lund University
Melanoma. Lund, Sweden
Malin Lindstedt
Lund University
Head and Neck Cancer. Lund, Sweden
Cristian Bellodi
Lund University
Epitranscriptomics. Lund, Sweden
Transgenic Core Facility
University of Copenhagen
Transgenic Mouse Model Generation. Copenhagen, Denmark
Drug Discovery and Development Platform
SciLifeLab
Small Molecule Screening. Stockholm, Sweden
Spin-Offs
Asgard Therapeutics
An important hallmark of cancer is the ability to evade the immune system. Asgard Therapeutics has the goal to establish dendritic cell reprogramming as an entirely new approach to unleash the immune system against cancer.
Blood Reprogramming Technologies
Blood Reprogramming Technologies is a biotechnology start-up focused on the use of direct cell reprogramming to generate innovative solutions for hematopoietic stem cell transplantation and blood regeneration.